Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2025
0mins
Source: PRnewswire
Merger and Reverse Stock Split: Aerovate Therapeutics' stockholders approved a merger with Jade Biosciences and a 1-for-35 reverse stock split, which will reduce Aerovate's outstanding shares from approximately 30 million to about 0.8 million, effective April 29, 2025.
Cash Dividend Announcement: A special cash dividend of $69.6 million, estimated at $2.40 per share, will be paid to Aerovate's stockholders on record as of April 25, 2025, unaffected by the reverse stock split.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
